Aclaris Therapeutics Inc
Company Profile
Business description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Contact
701 Lee Road
Suite 103
WaynePA19087
USAT: +1 484 324-7933
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
73
Stocks News & Analysis
stocks
Chart of the Week: AI proving a threat to company moats
stocks
ASX coal miners will benefit from higher prices
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,690.70 | 21.10 | -0.24% |
| CAC 40 | 7,845.43 | 124.45 | -1.56% |
| DAX 40 | 22,980.71 | 521.54 | -2.22% |
| Dow JONES (US) | 46,199.62 | 793.64 | -1.69% |
| FTSE 100 | 10,121.77 | 183.52 | -1.78% |
| HKSE | 25,500.58 | 524.84 | -2.02% |
| NASDAQ | 22,152.42 | 327.11 | -1.46% |
| Nikkei 225 | 53,372.53 | 1,866.87 | -3.38% |
| NZX 50 Index | 13,051.61 | 130.62 | -0.99% |
| S&P 500 | 6,626.82 | 89.27 | -1.33% |
| S&P/ASX 200 | 8,497.80 | 7.60 | -0.09% |
| SSE Composite Index | 4,006.55 | 56.43 | -1.39% |